TARAHealthcare · BiotechnologyTARA Stock Forecast: Protara Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Protara Therapeutics, Inc. hold a median 12-month price target of $26 — +531.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 8 Aug 2026 — in the upper half.
TARA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Protara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (74): The business earns solid, repeatable profits on what it owns.
Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Protara Therapeutics, Inc. — and when they’d sell — is the membership.
TARA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TARA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +531.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 May 2026 | Oppenheimer | Maintains | Outperform | $25 → $28 |
| 14 May 2026 | JP Morgan | Maintains | Overweight | $27 → $26 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Mar 2026 | JP Morgan | Initiates | Overweight | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 3 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2025 | Jones Trading | Initiates | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2025 | Scotiabank | Initiates | Sector Outperform | — |
| 14 Mar 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 11 Mar 2025 | LifeSci Capital | Initiates | Outperform | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Dec 2024 | Guggenheim | Reiterates | Buy | — |
| 6 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | Oppenheimer | Maintains | Outperform | — |
| 8 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TARA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Protara Therapeutics, Inc. (TARA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.1×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- −1.4×
Cheaper than 87% of US stocks
Cheaper than 66% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −37.3%
- Return on assets
- −24.3%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TARA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TARA appears on the weeks it earns a place.
Frequently asked questions about TARA stock
What is the TARA stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Protara Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $24 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TARA stock a buy right now?
Of the 8 analysts covering Protara Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protara Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TARA?
As at 8 Aug 2026, Protara Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (74 of 100).
Will TARA stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +531.1% from the last close, and Ticker Nerd's factor model ranks Protara Therapeutics, Inc. 50 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TARA stock forecast for 2030?
No analyst covering Protara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $30 over the next 12 months.
How has TARA stock performed over the past year?
Protara Therapeutics, Inc. returned +32.9% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Protara Therapeutics, Inc. do?
Protara Therapeutics Inc. is a biotechnology company focused on developing transformative therapies for rare and speciality diseases.
About Protara Therapeutics, Inc.
Protara Therapeutics Inc. is a biotechnology company focused on developing transformative therapies for rare and speciality diseases. The company's primary function is to innovate treatment solutions for conditions with significant unmet medical needs. One of Protara's notable ventures is in the development of intravenous therapy known as TARA-002, aimed at treating lymphatic malformations and non-muscle invasive bladder cancer. By orienting its efforts towards both oncology and the broader spectrum of rare diseases, Protara Therapeutics positions itself within crucial medical sectors that require advanced research and development. The company's impact extends to both patients and healthcare providers, filling treatment gaps left by traditional pharmaceutical offerings. Headquartered in New York, Protara operates at the forefront of medical innovation, contributing to the dynamic and rapidly-evolving landscape of biomedicine. By aligning itself with global healthcare objectives, Protara plays a significant role in enhancing patient outcomes and elevating the standards for medical research in specialized therapeutic areas.
CEO Mr. Jesse Shefferman · 46 employees · United States · https://www.protaratx.com